Published in J Immunol on May 01, 1975
Impaired cell-mediated immunity in Hodgkin's disease mediated by suppressor lymphocytes and monocytes. J Clin Invest (1978) 1.31
Ly 1+2- suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma. Immunology (1985) 1.08
Mechanisms of lymphocyte activation: the role of suppressor cells in the proliferative responses of chronic lymphatic leukemia lymphocytes. J Clin Invest (1979) 1.03
Studies on the pathogenesis of an immune defect in multiple myeloma. J Clin Invest (1977) 1.01
Decreased T lymphocyte migration in patients with malignancy mediated by a suppressor cell population. J Clin Invest (1984) 0.99
Radiation-induced augmentation of the response of A/J mice to SaI tumor cells. Am J Pathol (1982) 0.98
Occurrence of restricted suppressor T-cell activity in man. J Exp Med (1977) 0.95
Evidence that tumor antigens enhance tumor growth in vivo by interacting with a radiosensitive (suppressor?) cell population. Proc Natl Acad Sci U S A (1978) 0.93
Leukemia in AKR mice. I. Effects of leukemic cells on antibody-forming potential of syngeneic and allogeneic normal cells. J Exp Med (1976) 0.91
Suppressive effect of secondary Toxoplasma gondii infection on antibody responses in mice. Infect Immun (1985) 0.79
Suppression of lymphoproliferative responses to alloantigens by autologous AML cells. Clin Exp Immunol (1979) 0.78
Different responses of lymphoid cells from tumor-bearing as compared to tumor-immunized mice when sensitized to tumor specific antigens in vitro. Proc Natl Acad Sci U S A (1975) 0.77
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03
Identification of macrophage-like characteristics in a cultured murine tumor line. J Immunol (1975) 4.10
Quantitative in vitro assay of cytotoxic cellular immunity. J Natl Cancer Inst (1970) 3.12
Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am (1998) 2.14
T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. Cancer J (2001) 2.08
Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol (1999) 1.71
Enhanced immunogenicity of chemically-coated syngeneic tumor cells. Proc Natl Acad Sci U S A (1971) 1.55
Lymphocyte cytotoxicity reactions to leukemia-associated antigens in identical twins. Int J Cancer (1972) 1.55
Quantitative assessment of cellular and humoral responses to skin and tumor allografts. Transplantation (1971) 1.48
Qualitative and quantitative studies of cytotoxic immune cells. J Immunol (1971) 1.42
Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J Immunother (2000) 1.37
Filipin as a flow microfluorometry probe for cellular cholesterol. Cytometry (1984) 1.23
Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Hum Gene Ther (2000) 1.09
Targeted cytotoxic cells in human peripheral blood lymphocytes. J Immunol (1990) 1.02
Temporary inhibition of antibody-dependent, cell-mediated cytotoxicity by pretreatment of human attacking cells with ammonium chloride. J Immunol (1976) 1.01
Human T cells targeted with anti-T3 cross-linked to antitumor antibody prevent tumor growth in nude mice. J Immunol (1987) 0.94
Cytotoxicity mediated by human lymphocyte-dependent antibody in a rapid assay with adherent target cells. J Immunol (1973) 0.90
The use of freshly explanted mouse epidermal cells for the in vitro induction and detection of cell-mediated cytotoxicity. Cell Immunol (1976) 0.89
Changes in cell-surface expression of MHC and Thy-1.2 determinants following treatment with lipid modulating agents. J Immunol (1983) 0.88
Targeting of cytotoxic cells with heterocrosslinked antibodies. Cancer Invest (1988) 0.87
Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice. Cancer Res (1990) 0.85
T cell memory for the cytotoxic response to hapten-modified target cells. J Immunol (1976) 0.85
Autoradiographic and fluorescence antibody studies of the human host immune response to gliomas. Neurology (1972) 0.85
Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth. J Immunol (1991) 0.85
Cell mediated immunity induced in vitro. Nature (1970) 0.85
Identification of lymphocyte-dependent antibody in sera from multiply transfused patients. Transplantation (1974) 0.83
Rapid in vitro detection of cellular immunity in man against freshly explanted allogeneic cells. Transplantation (1972) 0.83
Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab')2 antibody prolong host survival in a murine xenograft model. Cancer Res (1991) 0.82
Going both ways: bispecific antibodies and targeted cellular cytotoxicity. FASEB J (1990) 0.82
The cellular nature of concanavalin A-stimulated antibody-dependent cell-mediated cytotoxicity. J Immunol (1980) 0.81
Evidence for the suppression of the development of cytotoxic lymphoid cells in tumor immunized mice. Fed Proc (1973) 0.81
Suppressed development of cytotoxic lymphoid cells in tumor-immunized mice. Isr J Med Sci (1973) 0.81
Immune response to an allogeneic progressively growing solid tumor. Cancer Res (1976) 0.79
Changes in mouse MHC expression during the cell cycle of Con A-treated spleen cells. J Immunol (1986) 0.78
Augmented antibody-dependent cell-mediated cytotoxicity following sensitization or nonspecific stimulation of human effector cells. Transplantation (1975) 0.78
In vivo immunization against autologous glioblastoma-associated antigens. Cancer Immunol Immunother (1985) 0.78
Targeted cytotoxic cells as a novel form of cancer immunotherapy. Mol Immunol (1988) 0.78
Targeting of cytotoxic cells against tumors with heterocrosslinked, bispecific antibodies. Princess Takamatsu Symp (1988) 0.78
In vitro and in vivo antitumor activity of lymphokine-induced cytotoxic cells. Int J Cancer (1985) 0.78
Cytokine release by peripheral blood lymphocytes targeted with bispecific antibodies, and its role in blocking tumor growth. Ann N Y Acad Sci (1991) 0.77
Bispecific antibodies retarget murine T cell cytotoxicity against syngeneic breast cancer in vitro and in vivo. Cancer Immunol Immunother (1995) 0.77
In vitro immunization against autologous glioblastoma cells coupled to adjuvant peptide. J Neurol Sci (1984) 0.77
Idiotypic control of the immune response. J Neuroimmunol (1988) 0.76
Treatment of experimental myasthenia with autologous idiotypes linked to muramyl dipeptide. Clin Exp Immunol (1988) 0.75
Complement-dependent and cell-dependent antiplatelet humoral antibody in sera from multi-transfused patients. Clin Exp Immunol (1975) 0.75
Antiglioma cytotoxic immune response. J Neurosurg (1994) 0.75
Chromium 51 cytotoxicity crossmatch monitoring cellular and humoral immunity in renal transplantation. Surg Forum (1972) 0.75
Hyperreactivity to myelin basic protein in multiple sclerosis. J Neurol Sci (1982) 0.75
Targeted cytokine production. Int J Cancer Suppl (1992) 0.75
Epidermal cells as targets and stimulators of allograft immunity in vitro. Transplant Proc (1977) 0.75
Targeting of anti-tumor responses with bispecific antibodies. Immunobiology (1992) 0.75
Functional efficiency of antitumor cytotoxic lymphoid cells. Isr J Med Sci (1973) 0.75
Refocusing the immune system to react with human tumors by targeting human lymphocytes with bispecific antibodies. Dev Biol Stand (1990) 0.75
Immune response of mice to concanavalin A-coated EL 4 leukemia. Natl Cancer Inst Monogr (1972) 0.75
Functional capacity of cytotoxic lymphoid cells. Natl Cancer Inst Monogr (1972) 0.75
Cell-mediated cytotoxic responses of spleen cells from mice bearing primary, chemically induced tumors. J Immunol (1979) 0.75
Tumor-specific immunogenicity induced by chemical modification. J Natl Cancer Inst (1976) 0.75
Supplement-induced cytotoxic cells (SICC) generated from mouse thymus or spleen cells cultured in the presence of interleukin 2 and/or polyinosinic acid. Cell Immunol (1983) 0.75
T cell nature of adjuvant peptide--induced antitumor cell-mediated cytotoxicity. J Biol Response Mod (1984) 0.75
Susceptibility of adherent versus suspension target cells derived from adherent tissue culture lines to cell-mediated cytotoxicity in rapid 51Cr-release assays. J Immunol Methods (1980) 0.75
Use of covalently bound cord factor analog to increase tumor immunogenicity. J Biol Response Mod (1984) 0.75
Chemical enhancement of tumor immunogenicity. J Immunol (1980) 0.75
Bacterial lipopolysaccharide acts synergistically with selected macromolecular polyanions to induce MHC-nonrestricted cytotoxic cells. Immunobiology (1991) 0.75
Direct cell-mediated cytotoxicity in experimental allergic encephalomyelitis. J Neurol Sci (1981) 0.75
Anti-HL-A7 lymphocyte-dependent antibody. Tissue Antigens (1975) 0.75